Esketamine As treatment for chronic pain due to endometrioSis: a RCT studY

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508417-16-00

Acronym

EASYlight-NEK

Enrollment

Registered

2024-01-18

Start date

2024-02-14

Completion date

Unknown

Last updated

2024-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Brief summary

NRS score for chronic pelvic pain 4 weeks after the 8 hour infusion treatment

Detailed description

Pain scores (NRS scores for dysmenorrhea, dyschezia, dysuria, dyspareunia and chronic pelvic pain), Treatment experience (including side-effects) (Bond&Ladder questionnaire, Bowdle questionnaire, treatment experience rating (on a scale of 0-10), Depressive symptoms (HADS), Quality of life (EHP-30, EQ-5D-5L), Cost-effectiveness (adjusted iPCQ, adjusted iMCQ), Pain coping and cognition (PCCL)

Interventions

DRUGSODIUM CHLORIDE

DRUGOndansetron Morningside 4 mg orodispergeerbare tabletten

DRUGOndansetron 2 mg/ml Solution for Injection

DRUGKetanest® S 5 mg/ml - Ampullen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
NRS score for chronic pelvic pain 4 weeks after the 8 hour infusion treatment	—

Secondary

Measure	Time frame
Pain scores (NRS scores for dysmenorrhea, dyschezia, dysuria, dyspareunia and chronic pelvic pain), Treatment experience (including side-effects) (Bond&Ladder questionnaire, Bowdle questionnaire, treatment experience rating (on a scale of 0-10), Depressive symptoms (HADS), Quality of life (EHP-30, EQ-5D-5L), Cost-effectiveness (adjusted iPCQ, adjusted iMCQ), Pain coping and cognition (PCCL)	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026